Drug Profile
Research programme: anticancer therapeutics - Fujitsu/Kowa/University of Tokyo
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Fujitsu; Kowa; University of Tokyo
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Cancer in Japan
- 01 Jun 2011 Early research in Cancer in Japan (unspecified route)